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A microwave enhanced synthesis of prodrug nucleotide (ProTide) analogues is presented. Comparison of
conventional thermal heating reaction with microwave irradiation exempliﬁes the potential of the novel
methodology herein presented for the selective 50-phosphoramidate synthesis, without protection of the
30 position in the ribonucleoside.Introduction
Microwave-Assisted Organic Synthesis (MAOS) has been widely
used in the last 40 years in the organic chemistry eld to solve
problems such as low yield, long reaction time, side reactions
and to synthesise libraries of compounds more eﬃciently. A
number of articles report the optimisation of a variety of
transformations exploiting the thermal/kinetic eﬀect of the
microwave irradiation (MWI) to enhance the reaction rate.1,2 A
few examples include Mitsunobu reaction,3 Suzuki coupling,4
Buchwald–Hartwig amination.5 Prodrug nucleotide (ProTide)
technology was originally designed by Professor Chris McGui-
gan and co-workers at Cardiﬀ University in the early 1990s.6 A
ProTide consists of a nucleoside where the negative charge on
the monophosphate moiety has been masked with an amino
acid ester and an aryl group (50-aryloxyphosphoramidate) to
deliver nucleotide analogues into the cell and to overcome
nucleoside drug resistance.7 The ProTide approach has been
successfully applied clinically: Sofosbuvir, Tenofovir alafena-
mide and Acelarin are clear examples of ProTide based drugs
used in the treatment of diﬀerent cancer and viral diseases.8
Interestingly, only one review drives the attention on the chal-
lenges in their synthetic preparation.9 Herein, we focus partic-
ularly on the nal step of the ProTide synthesis: the nucleoside
phosphoramidation, such as the coupling of the 50-hydroxy
moiety in the ribonucleoside with the phosphoramidating
reagent. The two synthetic approaches commonly applied to
perform this coupling are reported in Scheme 1.10 The rst
approach (Scheme 1, condition (a)) relies on the use of a strong
base to activate the nucleophile according to the Uchiyamaciences, Redwood Building, King Edward
brancalea@cardiﬀ.ac.uk
versity of Parma, Parco Area delle Scienze
SI) available: Additional conditions for
mental procedures and spectral data
54b
hemistry 2019method.11 In the second method (Scheme 1, condition (b)),
activation of the phosphoramidochloridate is performed by N-1-
methylimidazole (NMI).9,12
Although both methodologies have been extensively used to
synthesise several nucleoside prodrugs, a few limitations occur:
poor solubility of the parent nucleoside; low yield (10–42%);13
longer reaction time (4–48 hours);8,14,15 lack of 50-selectivity
which leads to the formation of unwanted 30,50-O,O-phosphor-
amidates (bis) by-products, when X is an hydroxyl group and Y is
either an hydroxy or hydrogen atom (Scheme 1).9
Also, appropriate protection of the sugar hydroxyl groups
and/or of the nucleobase oﬀers a solution to those limitations,
although it is not amenable to high throughput chemistry.
Additionally, protection/deprotection steps will require various
conditions and protecting groups depending on the diﬀerent
ribonucleoside and phosphoramidating reagent. Besides,
deprotection must be optimised to be compatible with the
ProTide moiety. While common synthetic procedures for the
synthesis of ProTide do not take into account the chirality at the
phosphorous atom, a paper by Pertusati focuses on the devel-
opment of a diastereoselective ProTide synthesis.14
Although, a suitable catalytic system to predominantly
deliver the Sp diastereoisomer via copper catalysis was identi-
ed, the new synthetic methodology still suﬀers from long
reaction time (8–12 h) and modest yields (12–66%).14Scheme 1 50-ProTide traditional synthetic approachesa. aBase:
adenine, guanine, cytosine, thymine, uracil. X ¼ –OH, –H, Y ¼ –OH,
–H. Reagent and conditions: (a) nucleoside, (8) (Z ¼ p-NO2-Ph), t-
BuMgCl, solvent, 0–25 C, 12–48 hours, 10–42% or (b) nucleoside,
NMI, (9) (Z ¼ –Cl), solvent, 25 C, 4–24 hours, 14–39%.
RSC Adv., 2019, 9, 20113–20117 | 20113
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View Article OnlineSommadossi and co-workers reported the use of the Grignard
method to synthesise a series of ProTide at 0 C over long reaction
time (15–18 h) and modest yields (16–55%).15 Recently, Simmons
and co-workers reported an optimised procedure to regioselectively
obtained the 50-phosphoramidate prodrugs of the ribonucleoside:
although their methodology was extensively validated on diﬀerent
pharmaceutically relevant ProTide, it still suﬀers from long reaction
times (20–48 hours).16 In this work, we aimed to develop a MAOS
methodology to obtain only the 50-ProTide in good yield over shorter
reaction time, without 30,50-O,O-phosphoramidates (bis-ProTide) by-
products formation, and without additional protection/
deprotection steps exploiting the cooling-while-heating (Power
Max option)17,18 on a CEMDiscover LabMate microwave synthesizer
for both the two aforementioned synthetic procedures reported in
Scheme 1. The cooling-while-heating MW technology further irra-
diates the reaction mixture with microwave power without over-
heating by simultaneously cooling down the reaction vessel with
compressed air. The target temperature is constant during the
microwave irradiation experiment. As aforementioned, the phos-
phoramidation reaction proceeds very slowly in conventional heat-
ing and with modest yield at 0 and 25 C. Then, we monitored the
prole of the conventionally heated reaction at higher temperature,
such as 55 C. Preliminary experiments demonstrated that in
conventional heating, a further increase in temperature would have
not been compatible with long reaction times required to observe
the formation of the desired product. When the reaction mixture
was irradiated under standard MWI method at 55 C (xed power,
100 W), there was not a benecial eﬀect on the formation of the
desired product (microwave power absorbed by reaction mixture
was 6 W). We then repeated the same experiment using the
temperature xed mode: we xed the temperature at 55 C and the
MW irradiated the reaction mixture with as much power as the
reactionmixture was able to absorb. Having observed the formation
of the desired product, we then tried to optimise the MWI condi-
tions.We initially exploited the eﬀect of a 10 C increase underMWI
(xed temperature mode, dynamic method) and monitor how the
percentage of conversion to the desired product was inuenced
(microwave power absorbed in cooling-while-heating experiment
was 100W). Then, we investigated the eﬀect of diﬀerent solvents on
both solubility and microwave power absorption (using both low
and high microwave absorbing solvents), diﬀerent reaction times
and temperatures under conventional and MW heating. Reactions
in conventional heating or under microwave irradiation were per-
formed using the same number of equivalents of reagents, the same
molarity for the solution of the reaction mixture, in closed vessel
and under anhydrous conditions to avoid any eﬀects of air/moisture
stability of reagents, and evaporation of solvents. Finally, we
compared the yields and the reaction times for each experiment in
the same experimental conditions under both conventional heating
and microwave irradiation.Results and discussion
To exemplify the potential of the application of the MWI to the
nucleoside phosphoramidation, we started our studies using the
protected adenosine (17) for the initial model reaction.1920114 | RSC Adv., 2019, 9, 20113–20117The, we conrmed the compatibility of our microwave based
approach using several phosphoramidating agents, exploring
diﬀerent leaving groups (para-nitrophenolate, chlorine atom,
phenol) and ester moiety (benzyl, iso-propyl), as reported in Table
1.
Initially, we used a near-stoichiometric amount of Grignard
reagent (2 equivalents) and amixture of tetrahydrofuran (THF) and
N-methyl-2-pyrrolidone (NMP).11 We compared the yield achieved
in the conventional and MWI heating modes (Table 1).
Under MWI, we observed a remarkable reduction in the
reaction times for all the diﬀerent phosphoramidating reagents
(8, 9, 18–21) and mostly also an improvement in the isolated
yield. Encouraged by these results, we explored the cooling-
while-heating MWI using diﬀerent nucleosides in comparison
to conventional heating reactions. Briey, we initially used the
same conditions as the ones applied to the protected adenosine
17 for both conventional heating and MWI experiments in
terms of reagent stoichiometry and solvent system. When we
observed a lack of reactivity or longer reaction times under
MWI, we screened a diﬀerent panel of conditions. The diﬀerent
parameters we investigated on the unprotected nucleosides (1–
7) include: the stoichiometry of the Grignard reagent to ensure
the O-selective condensation; the solvent to improve solubility
of the parent nucleoside and maximise the absorbance of the
microwave power using solvents with high tan d; temperature in
the MWI reaction to enhance the yield, while simultaneously
shortening the reaction time. Detailed conditions and results of
the optimisation study are listed in Section 3 of the ESI.† Here
in Table 2, we report the best conditions for both synthetic
methodologies as a comparison of the MWI against conven-
tional heating mode for seven nucleosides (1–7). Initially, we
applied the conditions used in the protected adenosine (17), to
the unprotected nucleoside (1). Although yields were compa-
rable, a 30-fold shorter reaction time was observed under MWI.
Furthermore, the MWI mode did not aﬀect selectivity towards
50-product formation since bis-product was not detected (Table 2,
entry 1). In the NMI method, THF and pyridine solvent mixture
furnished the target 50-product (10) in good yield in 20 minutes
(Table 2 – entry 2). Although, pyridine tan d is not reported in the
literature, we believe its benecial eﬀect on the reaction mixture
under MWI can be explained by its polar nature. To solve solu-
bility limitation in the cytidine based ProTide synthesis, we focus
our eﬀort on the identication of a suitable solvent system. Cyti-
dine proved to be insoluble in several solvent systems, such as 1,4-
dioxane, THF alone and in co-mixture with NMP or pyridine. The
use of the polar and high microwave coupling solvent N,N-dime-
thylformamide (DMF, tan d ¼ 0.161) considerably improved
solubility and increased the yield (Table 2, entry 3), with a 10-fold
shortening of the reaction time under MWI. In the NMI method,
solubility of the ribonucleoside (2) was only slightly improved
using a solvent mixture of THF/pyridine, and the yield dramati-
cally decreased (Table 2, entry 4). Driven by the results achieved
with cytidine, we further conrmed the benecial eﬀect of DMF
also on the 20,30-dideoxycytidine (3). As expected, yield steadily
improved in the microwave irradiation reaction for both synthetic
approaches. Particularly because of the enhanced solubility and
lack of 20,30 hydroxyl groups, in the Grignardmethod with a 20 CThis journal is © The Royal Society of Chemistry 2019
Table 1 Protected adenosine phosphoramidate (22)–(23)a
Entry Reagents Solvent
Conventional heating (55 C) Microwave irradiation* (65 C)
Time (min) Yield** (%) (22) or (23) Hold time (min)***
Yield**
(%) (22) or (23)
1a t-BuMgCl + (8) THF/NMP 150 34 (22) 2.5 41 (22)
2a 30 81 (22)
3a NMI + (9) THF/NMP 120 55 (22) 15 28 (22)
4b t-BuMgCl + (18) THF/NMP 30 77 (23) 2 67 (23)
5a NMI + (19) THF/NMP 120 55 (22) 15 28 (22)
6a t-BuMgCl + (19) THF/NMP 15 52 (23) 2 36 (23)
7a t-BuMgCl + (20) THF/NMP 1440 29 (22) 60 42 (22)
8a t-BuMgCl + (21) THF/NMP 480 15 (23) 60 28 (23)
a Reaction conditions: (a) compound 17 (1 equivalent), t-BuMgCl (2 equivalent), compound 8 or 18 or 20 or 21 (2 equivalent), solvent (2mLmmol1);
(b) compound 17 (1 equivalent), NMI (6 equivalent), compound 9 or 19 (2 equivalent), solvent (2 mL mmol1). For both conditions, ratio THF/NMP
is 4.8 : 1. *Microwave PowerMax set at 300 W. Maximum microwave power absorbed by reaction mixture 100 W. **Yields were calculated on the
isolated product aer automated ash column chromatography purication. ***Hold time reported here does not include 25 s of ramping time
to go from 25 C to target temperature and 50 s to cool down the reaction vessel at 25 C aer MWI.
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View Article Onlineincrease in temperature under MWI, the desired product 12 was
formed in an excellent yield and with a 27-fold reduction of the
reaction time (Table 2, entry 5). Interestingly, in the NMI method,
a 10 C increase in the MWI reaction resulted in a 30-fold shorter
reaction time (Table 2, entry 6). Then, we focused on the condi-
tions optimisation for guanosine (4). To promote the kinetic of the
reaction, we sought to simultaneously increase the equivalents of
Grignard reagent and the reaction temperature in the microwave
heating system, using DMF as solvent. In this case, we observed
an excellent percentage of conversion of the parent nucleoside
into the desired 50-ProTide (13) (Table 2, entry 7) achieving
a considerable decrease in the reaction time. Since guanosine (4)
was unreactive in the NMI conditions, we simultaneously acti-
vated the 50-hydroxy group on the ribose using the tert-butyl
magnesium chloride and the phosphoramidating reagent upon
treatment with the NMI (ESI, S30,† Table 2, entry 14) without any
success. To the best of our eﬀorts, we could observe only a 13%
conversion in the desired compound (13), over a signicantly
shorter (10 minutes) reaction time (Table 2, entry 8). When we
irradiated uridine (5) with microwave power, in the Grignard
driven method, using THF/NMP as solvent, we successfully ach-
ieved the formation of the mono product (14) in only 15 minutes
(20-fold reduction in reaction time) and good yield (38%). Then, in
the NMI based methodology, the conversion of the parent
nucleoside in the desired product (14) was achieved in good yieldThis journal is © The Royal Society of Chemistry 2019(Table 2, entry 10) with a 10-fold reduction of the reaction time
(Table 2 – entries 9 and 10). With thymidine (6), the use of
diﬀerent solvent systems proved to be unsuccessful as increasing
the Grignard reagent equivalents. Hence, we decided to clarify
whether the rate of addition of both base and phoshoramidating
reagentmay play an important role in driving the formation of the
50-phosphoramidate. The portion wise addition of both the base
and the phosphoramidating reagent in the Grignard method,
selectively promotes the formation of the desired product (15),
halving the reaction time in the MW irradiated reaction, limiting
the formation of the bis product (24, Table 2 – entry 11). In the
NMI method, we achieved the formation of the target compound
(15) in comparable yield between the two heating systems, but
with a remarkable decrease of the reaction time (48-fold shorter)
in MWI optimised experiment (Table 2, entry 12). In the 20-deox-
ythymidine (7) optimisation of the Grignard method, the use of
DMF allows to overcome the solubility issues and to increase the
absorbance of microwave power. Then, we shortened the reaction
time by increasing the reaction temperature in the MW vessel. In
the NMI based method, we observed formation of the mono
product (16) in excellent yield (81–89%) with a 150–52 fold
shortening of the reaction time for both methodologies. To the
best of our knowledge, this was the rst application of the
microwave irradiation to the phosphoramidation reaction in the
synthetic preparation of the ProTides.RSC Adv., 2019, 9, 20113–20117 | 20115
Table 2 Nucleoside phosphoramidates (10–16) and by-products (24)a
Base Nucleoside X Y 50-ProTide 30,50-ProTide
Adenine (1) –OH –OH (10) —
Cytosine (2) –OH –OH (11) —
Cytosine (3) –H –H (12) —
Guanine (4) –OH –OH (13) —
Uracil (5) –OH –OH (14) —
Thymine (6) –OH –OH (15) (24)
Thymine (7) –H –H (16) —
Entry Nucleoside Solvent
Conventional heating (55 C) Microwave irradiation
Time
(min)
Yield (%)**
Hold time
(min)***
Temperature
(C)
Yield (%)**
Nucleoside
50-
ProTide
50,30-
ProTide Nucleoside
50-
ProTide
50,30-
ProTide
1a (1) THF/NMP 60 58 (1) 42 (10) — 2 65 60 (1) 40 (10) —
2b (1) THF/
pyridine
180 45 (1) 55 (10) — 20 85 38 (1) 61 (10)
3a (2) DMF 200 48 (2) 51 (11) — 25 65 19 (2) 81 (11) —
4b (2) THF/
pyridine
300 44 (2) 55 (11) — 25 65 89 (2) 11 (11) —
5a (3) DMF 135 1 (3) 99 (12) — 5 75 19 (3) 81 (12) —
6b (3) THF 300 47 (3) 53 (12) — 10 65 10 (3) 90 (12) —
7a (4) DMF 450 34 (4) 66 (13) — 10 75 12 (4) 88 (13) —
8b (4) THF/
pyridine
1440 51 (4) 49 (13) — 35 65 87 (4) 13 (13) —
9a (5) THF/NMP 320 62 (5) 38 (14) — 15 65 62 (5) 38 (14) —
10b (5) THF 350 35 (5) 65 (14) — 35 65 46 (5) 54 (14) —
11a,* (6) THF/NMP 120 16 (6) 45 (15) 39 (24) 60 65 54 (6) 43 (15) 3 (24)
12b (6) THF 240 13 (6) 73 (15) 14 (24) 5 65 1 (6) 70 (15) 29 (24)
13a (7) DMF 150 2 (7) 98 (16) — 1 65 19 (7) 81 (16) —
14b (7) THF 155 16 (7) 84 (16) — 3 65 11 (7) 89 (16) —
a Reagent and conditions: (a) t-BuMgCl (3 equivalents), (8), solvent (0.1 M. For THF/pyridine or THF/NMP: ratio was 4.8 : 1); (b) NMI (6.3
equivalents), (9), solvent (0.1 M. For THF/pyridine or THF/NMP: ratio was 4.8 : 1). *In this case, 0.5 equivalent of t-BuMgCl were added for 4
times (total of 2 equivalents). **Yield determined as percentage of conversion of the parent nucleoside in the desired mono substituted product
and/or undesired bis substituted product by HPLC/UPLC analysis. ***Hold time reported here does not include 25 s of ramping time to go
from 25 C to target temperature and 50 s to cool down the reaction vessel at 25 C aer MWI.
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View Article OnlineConclusions
Microwave assisted synthesis has been successfully applied to
a number of ribonucleoside and deoxyribonucleoside bearing
diﬀerent bases and using variously substituted phosphor-
amidating reagents. We achieved formation of the desired 50-
ProTide in good to excellent (13–97%) yields, with a considerably20116 | RSC Adv., 2019, 9, 20113–20117shortening of the reaction time (2–150 times decrease). Addi-
tionally, with thymidine nucleosides (Table 2 – entries 3–7),
microwave irradiation proved to promote the selective 50-phos-
phoramidation contrary to the thermal heating where the bis by-
side product was predominantly formed. This optimised meth-
odology may be applied to facilitate the synthesis of novel phar-
maceutically relevant ProTides in the future.This journal is © The Royal Society of Chemistry 2019
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